Association between Statins and Prostate Tumor Inflammatory Infiltrate in Men Undergoing Radical Prostatectomy
Association between Statins and Prostate Tumor Inflammatory Infiltrate in Men Undergoing Radical Prostatectomy
复制标题
DOI：
10.1158/1055-9965.epi-09-1074
复制
发表时间：
2010-03-01
影响因子：
3.8
通讯作者：
Freedland, Stephen J.
中科院分区：
文献类型：
--
作者：
Banez, Lionel L.;Klink, Joseph C.;Freedland, Stephen J.
背景：降胆固醇药物他汀类药物被报道具有显著的抗炎作用。鉴于炎症可能导致前列腺癌的进展，他汀类药物可能降低晚期前列腺癌的风险，我们研究了他汀类药物的使用是否与根治性前列腺切除术（RP）标本中肿瘤内炎症的减少有关。方法：从1996年到2004年，236名接受RP的男性的索引肿瘤内的炎症由一位病理学家分级为0级（无），1级（无），2级（无），3级（无），4级（无），5级（无），6级（无），7级（无），8级（无），10级（轻度：10%）。术前他汀类药物的使用通过将受试者分组为他汀类药物使用者或非使用者进行分析。使用20 mg辛伐他汀的剂量当量作为参考，说明他汀类药物的类型和剂量。Logistic回归分析用于确定他汀类药物使用与肿瘤内炎症之间的关系，控制年龄、种族、体重指数、前列腺特异性抗原、手术年、临床分期、病理Gleason总和、手术切缘状态、囊外扩张、精囊浸润、前列腺重量、前列腺活检至RP的时间和非甾体抗炎药使用。术前使用他汀类药物与任何（等级>= 1）肿瘤内炎症（比值比，0.31; 95%可信区间，0.10-0.98; P = 0.047），剂量>= 20 mg辛伐他汀当量更强相关（相对于不使用;比值比，0.22; 95%可信区间，0.06-0.79; P = 0.02）结论：在接受RP的男性队列中，他汀类药物的使用与前列腺肿瘤内任何炎症的风险显著降低相关。影响：鉴于先前的报道，炎症与晚期前列腺癌相关，他汀类药物的使用与前列腺癌进展风险降低相关，我们的研究结果表明，抑制肿瘤内的炎症可能是他汀类药物所谓的抗前列腺癌特性的潜在机制。癌症流行病学生物标志物Prev; 19（3）; 722-8。(C)2010年AACR。
Background: Cholesterol-lowering drugs known as statins have been reported to have significant anti-inflammatory properties. Given that inflammation may contribute to prostate cancer progression and that statins may reduce the risk for advanced prostate cancer, we investigated whether statin use was associated with reduced intratumoral inflammation in radical prostatectomy (RP) specimens.Methods: Inflammation within index tumors of 236 men undergoing RP from 1996 to 2004 was graded by a single pathologist as grade 0 (absent), 1 (mild: 10%). Preoperative statin use was analyzed by grouping subjects as statin users or nonusers. Type and dosage of statin was accounted for using dose equivalents with 20 mg simvastatin as reference. Logistic regression was used to determine the association between statin use and intratumoral inflammation controlling for age, race, body mass index, prostatespecific antigen, year of surgery, clinical stage, pathologic Gleason sum, surgical margin status, extracapsular extension, seminal vesicle invasion, prostate weight, time from prostate biopsy to RP, and nonsteroidal anti-inflammatory drug use.Results: Preoperative statin use was significantly associated with lower risk for any (grade >= 1) intratumoral inflammation (odds ratio, 0.31; 95% confidence interval, 0.10-0.98; P = 0.047) on multivariable analysis, with doses >= 20 mg simvastatin equivalents being more strongly associated (relative to nonuse; odds ratio, 0.22; 95% confidence interval, 0.06-0.79; P = 0.02).Conclusion: In a cohort of men undergoing RP, statin use was associated with significantly lower risk of any inflammation within prostate tumors. Impact: Given previous reports that inflammation is associated with advanced prostate cancer, and statin use is associated with decreased prostate cancer progression risk, our findings suggest that inhibition of inflammation within tumors may be a potential mechanism for purported anti-prostate cancer properties of statins. Cancer Epidemiol Biomarkers Prev; 19(3); 722-8. (C) 2010 AACR.